8-K: OpGen Announces 1-for-10 Reverse Stock Split and Amendment to EIB Settlement Agreement

OpGen, Inc. has announced a 1-for-10 reverse stock split to regain compliance with Nasdaq listing requirements and has amended its settlement agreement with the European Investment Bank to extend payment deadlines.

Summary

• OpGen has enacted a 1-for-10 reverse stock split of its common stock, effective May 20, 2024.
• The reverse stock split aims to increase the stock price to meet Nasdaq's minimum bid price requirement of $1.00 per share.
• The number of outstanding shares will decrease from approximately 12,624,902 to approximately 1,262,490.
• The company has also amended its settlement agreement with the European Investment Bank (EIB), extending the payment deadline to June 3, 2024.
• This extension was necessary due to a delay in filing the company's annual report on Form 10-K for the fiscal year ended December 31, 2023.

Sentiment

Score: 3

Explanation: The document highlights a reverse stock split and a payment delay, both of which are generally negative indicators for a company's financial health and operational efficiency. While the company is taking steps to address these issues, the overall sentiment is negative.

Positives

• The reverse stock split is a proactive measure to regain compliance with Nasdaq listing requirements.
• The amendment to the EIB settlement agreement provides additional time to fulfill payment obligations.

Negatives

• The delay in filing the 10-K annual report necessitated an amendment to the EIB settlement agreement.
• The reverse stock split indicates that the company's stock price was below the Nasdaq minimum bid price requirement.

Risks

• The company's ability to regain compliance with Nasdaq listing rules is not guaranteed.
• The company's ability to continue to finance its business and operations is subject to risks and uncertainties.
• The company's liquidity and working capital requirements may pose challenges.

Future Outlook

The company aims to regain compliance with Nasdaq listing rules through the reverse stock split, but faces risks related to financing and liquidity.

Management Comments

• The company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock.
• The reverse stock split is expected to increase the market price per share of common stock in order to regain compliance with The Nasdaq Capital Markets minimum bid price listing requirement of $1.00 per share.

Industry Context

Reverse stock splits are often used by companies facing delisting from major exchanges due to low stock prices, indicating potential financial challenges or a need to improve investor perception.

Comparison to Industry Standards

• Many companies facing similar listing compliance issues have used reverse stock splits to increase their share price.
• The 1-for-10 ratio is a common ratio for reverse stock splits, but the success of such actions varies widely depending on the company's underlying financial health and market conditions.
• Other companies in the biotech sector, such as Agenus Inc. and VBI Vaccines Inc., have also recently undertaken reverse stock splits to maintain their Nasdaq listings.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but their percentage ownership will remain the same (except for fractional shares).
• The reverse stock split may impact the market perception of the company.
• The company's ability to meet its financial obligations to the EIB is crucial for maintaining creditor confidence.

Next Steps

• The company will continue to trade on The Nasdaq Capital Market under the symbol OPGN on a split-adjusted basis.
• The company will make the settlement payment to the EIB by June 3, 2024.
• The company will need to regain compliance with Nasdaq listing rules.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, European Investment Bank, settlement agreement, 10-K filing, stock price, common stock, amendment agreement